



Press Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and COO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Junichi Onuma,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<https://www.daiichisankyo.com>

Daiichi Sankyo Announces Launch of Oxycodone Injections “Daiichi Sankyo” for Cancer Pain Treatment in Japan

Tokyo, Japan (June 14, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new generic formulation of oxycodone hydrochloride hydrate injection for cancer pain treatment, Oxycodone Injections 10 mg and 50 mg “Daiichi Sankyo” (hereafter, new formulation), in Japan.

The new formulation is the first generic injection containing oxycodone hydrochloride, a strong opioid analgesic providing relief of moderate to severe pain in various types of cancer.

It is manufactured from drug substance to formulation solely by Daiichi Sankyo’s subsidiary in Japan, Daiichi Sankyo Propharma Co., Ltd. (marketing authorization holder).

The addition of the new formulation to our product lineup of opioid analgesics will provide another treatment option for patients suffering from cancer pain and further enhance our contribution to healthcare in Japan.

Product Summary

Product Name	Therapeutic Category	Original Brand Name
Oxycodone Injections 10 mg “Daiichi Sankyo”	Cancer pain treatment	OxiFast® Injection 10 mg
Oxycodone Injections 50 mg “Daiichi Sankyo”		OxiFast® Injection 50 mg

About Daiichi Sankyo Opioid Analgesics in Japan

Daiichi Sankyo aims to contribute to the total care of patients with cancer for their lives by our opioid analgesics.

Daiichi Sankyo believes that expanding our product lineup of opioid analgesics provides support for patients living with cancer by improving their quality of life through pain relief.

Opioid analgesics sold in Japan by Daiichi Sankyo comprise the hydromorphone hydrochloride formulations Narusus[®] Tablets (extended release formulation), Narurapid[®] Tablets (immediate release formulation) and Naruvein[®] Injection (injection formulation), the oxycodone hydrochloride formulations Oxycodone Extended Release Tablets “Daiichi Sankyo” (extended release formulation) and Oxycodone Tablets “Daiichi Sankyo” (immediate release formulation) and Oxycodone Injections “Daiichi Sankyo” that has just been launched, as well as the fentanyl citrate tape formulation Fentanyl Citrate Tape for 1 day “Daiichi Sankyo” (transdermal absorption formulation).